Role of Akt signaling in resistance to DNA-targeted therapy

Table 2 Systematic chart of searching methodology and the results based on PubMed

DNA-targeted therapies	Agents	Akt modulation
		All papers1	Non-original2	Relevant papers3	PI3K/Akt inhibitors4
					LY294002	Wortmannin	BEZ235	Perifosine	MK2206
Platinum	Carboplatin	68	6	51	3	1	0	0	4
	Cisplatin	631	15	589	85	22	8	9	5
	Oxaliplatin	71	5	59	5	2	0	0	0
Taxane	Docetaxel	149	13	127	9	2	3	1	3
	Paclitaxel	363	18	331	47	15	4	2	5
Antimetabolite	Fluorouracil	191	5	174	18	6	0	2	3
	Gemcitabine	213	14	191	16	8	3	1	1
	Pemetrexed	35	3	32	5	2	1	0	0
Radiation	Irradiation/radiation	1649	186	1356	151	82	12	13	5
Total articles	(9 agents)	3370	265	2910	339	140	31	28	26

¹Terms used in the search: Query agent/radiation, and Akt, within whole the article with no language limitation, as of September, 2014;

²Including the retracted publication, duplicate publication or non-original papers, including Review articles, Letters and Editorials, Comments, Case Reports, etc.;

³Relevant with regard to the modulation of Akt by the query agent. [p-Akt OR pAkt OR "phospho-Akt" OR (phosphorylat* Akt) OR “Akt phosphorylation” OR “Akt inhibition” OR “Akt modulation” OR (inhibit* Akt) OR “inactivation of Akt” OR “Akt inactivation” OR “activation of Akt” OR “inactivating Akt”];

⁴Suppressing Akt cascade by a PI3K/Akt inhibitor to sensitize the query agent. PI3K: Phosphatidylinositol 3 kinase.